Table 1 Characteristics of included studies. SSC therapy: Surviving Sepisis Campaign therapy
Study | Population | Case number, Tα1/control | Interventions in Tα1 group | Interventions in control group | Outcomes |
|---|---|---|---|---|---|
Chen XL 2009 [25] | Sepsis patients in ICU, age over 18 years | 40, 20/20 | SSC therapy + Tα1, 1.6 mg,SC,QD | SSC therapy + NS | Levels of CD3,CD4,CD8, CD4/CD8, NK,CRP, APACHE II |
Cheng AB 2010 [26] | Sepsis patients in ICU, age under 70 years and HLA-DR < 30 % | 60,30/30 | Conventional treatment + Tα1, 1.6 mg, SC, QD | Conventional treatment + NS | Levels of CD4,CD8 and HLA-DR |
Gui CM 2012 [27] | Sepsis patients in ICU, age between 18 and 80 years | 42,22/20 | SSC therapy + Tα1, 1.6 mg,SC,QD | SSC therapy | Levels of CD4, CD4/CD8, igg, iga, igm, PCT, IL-6, IL-10 and APACHE II |
Hu XL 2007 [28] | Abdominal sepsis patients in ICU | 45,24/21 | Conventional treatment + Tα1, 1.6 mg, SC, QD | Conventional treatment + NS | Levels of TNF-α, IL-6, IL-10, CD3,CD4,CD8, CD4/CD8, NK and 28-day mortality |
Gong ZH 2011 [29] | Burn sepsis patients | 56,28/28 | Conventional treatment + Tα1, 1.6 mg, SC, QD | Conventional treatment | Levels of TNF-α, and WBC |
Chen J 2007 [38] | Septic shock, APACHE II scores between 15 and 20 | 42,21/21 | SSC therapy + Tα1, 1.6 mg,SC, BID | SSC therapy | Levels of T-lymphocyte subtype, natural killer cell and mechanical ventilation time, length of ICU stay, 28-day mortality |
Fan JB 2014 [30] | Sepsis patients or septic shock | 120,60/60 | Conventional treatment + Tα1, 1.6 mg, SC, QD | Conventional treatment | Levels of CD4, CD8, CD4/CD8, APACHE II and 28-day mortality |
Lei S 2005 [37] | Severe hospital acquired pneumonia patients in ICU, HLA-DR <30 %, | 38,21/17 | Conventional treatment + Tα1, 1.6 mg, SC, BID | Conventional treatment | Levels of CD4, CD8, CD4/CD8, NK, HLA-DR and 28-day mortality |
Li YN 2009 [31] | Age over 18 years, suffering from severe sepsis with Marshall score over 5 | 47, 23/24 | SSC therapy + Tα1, 1.6 mg,SC, QD | SSC therapy | Levels of HLA-DR, CD3, CD4, CD8, length of ICU stay, APACHE II, 28-day mortality and mechanical ventilation time |
Wu JN 2004 [32] | Sepsis patients in ICU, HLA-DR <30 % | 44,22/22 | Conventional treatment + Tα1, 1.6 mg, SC, QD | Conventional treatment + NS | Levels of HLA-DR, CRP, APACHE II; and MOF |
Wu JF 2013 [39] | Patients in ICU with severe sepsis | 361,181/180 | Conventional treatment + Tα1, 1.6 mg, SC, twice per day for 5 consecutive days, then once per day for 2 consecutive days | Conventional treatment + NS | Levels of HLA-DR, CD4/CD8, WBC, duration of ICU stay, mechanical ventilation time, APACHE II and 28-day mortality |
Wu JF 2014 [40] | Sepsis patients, age over 18 years | 54,26/28 | Conventional treatment + Tα1, 1.6 mg, SC, twice per day for 5 consecutive days, then once per day for 2 consecutive days | Conventional treatment | 28-day mortality |
Zhang BJ 2014 [41] | Sepsis patients | 60,30/30 | Conventional treatment + Tα1, 1.6 mg, SC, twice per day | Conventional treatment | Level of IL-6 and APACHE II |
Zhang Z 2006 [33] | Sepsis patients | 38,19/19 | Conventional treatment + Tα1, 1.6 mg, SC, QD | Conventional treatment | Levels of CRP, CD3, CD4, CD8, CD4/CD8, NK, and APACHE II |
Zhou LX 2009 [35] | Severe sepsis aged > 18, Marshall score > 5 | 47, 23/24 | Tα1 plus SSC therapy | SSC therapy | IL-6, IL-10, TNF-α, HLA-DR, T lymphocytes, 28-day mortality |
Zhao MY 2007 [34] | Sepsis patients in ICU, HLA-DR <30 %, age <70 | 42,21/21 | Conventional treatment + Tα1, 1.6 mg, SC,QD | Conventional treatment + NS | Levels of HLA-DR, CD4, CD8, TNF-α,IL-6 and IL-10 |
Zhou Q 2011 [36] | Severe sepsis, age > 18 years | 82,42/40 | SSC therapy + Tα1, 1.6 mg,SC,QD | SSC therapy | Levels of HLA-DR, CD3, CD4, CD8, CD4/CD8 |
Zhu 2015 [43] | Severe sepsis, age > 18 years | 60,30/30 | Conventional treatment + Tα1, 1.6 mg, SC, QD | Conventional treatment + NS | Levels of, CD3, CD4, CD8, CD4/CD8, duration of ICU stay and APACHE II |
Lu 2015 [42] | Patients with siai, age > 18 years | 76,38/38 | Conventional treatment + Tα1, 1.6 mg, SC, twice a week | Conventional treatment + NS | Levels of, CD3, CD4, CD8, CD4/CD8 |